Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BNTC logo BNTC
Upturn stock ratingUpturn stock rating
BNTC logo

Benitec Biopharma Ltd ADR (BNTC)

Upturn stock ratingUpturn stock rating
$14.94
Last Close (24-hour delay)
Profit since last BUY-4.17%
upturn advisory
Consider higher Upturn Star rating
BUY since 15 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/18/2025: BNTC (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $25.71

Year Target Price $25.71

Analyst’s Price TargetsFor last 52 week
$25.71Target price
Low$7.05
Current$14.94
high$17.15

Analysis of Past Performance

Type Stock
Historic Profit 7.29%
Avg. Invested days 28
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/18/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 297.94M USD
Price to earnings Ratio -
1Y Target Price 25.71
Price to earnings Ratio -
1Y Target Price 25.71
Volume (30-day avg) -
Beta 0.44
52 Weeks Range 7.05 - 17.15
Updated Date 06/29/2025
52 Weeks Range 7.05 - 17.15
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -5.03

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -31.34%
Return on Equity (TTM) -48.57%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 192562523
Price to Sales(TTM) 2770.13
Enterprise Value 192562523
Price to Sales(TTM) 2770.13
Enterprise Value to Revenue 10457.68
Enterprise Value to EBITDA 0.27
Shares Outstanding 26250500
Shares Floating 12567143
Shares Outstanding 26250500
Shares Floating 12567143
Percent Insiders 3.12
Percent Institutions 85.16

Analyst Ratings

Rating 4.57
Target Price 25.71
Buy 3
Strong Buy 4
Buy 3
Strong Buy 4
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Benitec Biopharma Ltd ADR

stock logo

Company Overview

overview logo History and Background

Benitec Biopharma Ltd, established in 1997, is a biotechnology company focused on developing novel genetic medicines using its proprietary DNA-directed RNA interference (ddRNAi) platform technology. It has gone through multiple phases, including restructuring and focusing on specific therapeutic areas.

business area logo Core Business Areas

  • Oncology: Benitec is focused on developing ddRNAi-based therapeutics for oncology, targeting specific genes involved in cancer development and progression.
  • Ophthalmology: Benitec explores ddRNAi applications for ophthalmological disorders, aiming to address diseases affecting vision.

leadership logo Leadership and Structure

Benitec Biopharma Ltd. is led by a management team with experience in biotechnology and drug development. The organizational structure includes departments for research and development, clinical operations, and corporate functions.

Top Products and Market Share

overview logo Key Offerings

  • BB-301: BB-301 is Benitec's leading clinical program, targeting Oculopharyngeal Muscular Dystrophy (OPMD). There is no current market share as the product is still in development. Competitors include companies developing gene therapies for muscular dystrophies.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. Gene therapy is a growing field with significant potential.

Positioning

Benitec is a smaller player in the gene therapy space, focusing on ddRNAi technology. Its competitive advantage lies in the potential of its platform to offer targeted gene silencing.

Total Addressable Market (TAM)

The TAM for gene therapies addressing specific genetic disorders can be substantial, potentially reaching billions of dollars. Benitec's positioning depends on the successful clinical development and commercialization of its lead programs.

Upturn SWOT Analysis

Strengths

  • Proprietary ddRNAi technology
  • Focus on specific disease areas
  • Experienced management team

Weaknesses

  • Limited financial resources
  • Reliance on single platform technology
  • Early stage clinical development

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Positive clinical trial results

Threats

  • Competition from established gene therapy companies
  • Regulatory hurdles
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • CRSP
  • EDIT
  • NTLA
  • SRPT

Competitive Landscape

Benitec faces competition from larger, more established gene therapy companies. Its success depends on differentiating its ddRNAi platform and achieving positive clinical outcomes.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited due to its developmental stage. Future growth depends on clinical trial success.

Future Projections: Future projections are highly dependent on successful clinical outcomes and regulatory approvals.

Recent Initiatives: Recent initiatives include advancing clinical programs and exploring potential partnerships.

Summary

Benitec Biopharma is a high-risk, high-reward biotechnology company. Its ddRNAi technology has potential, but it faces challenges with clinical development, funding, and competition. Success hinges on its ability to execute its clinical programs and potentially partner with larger pharmaceutical companies. Its current financial structure means there is a risk of delisting due to the stock price.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Industry reports
  • Analyst reports

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investment decisions should be made in consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Benitec Biopharma Ltd ADR

Exchange NASDAQ
Headquaters Hayward, CA, United States
IPO Launch date 2015-08-18
Executive Chairman & CEO Dr. Jerel A. Banks M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 16
Full time employees 16

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.